Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intrauterine Devices | 4 | 2013 | 33 | 1.350 |
Why?
|
| Primary Health Care | 5 | 2021 | 392 | 1.140 |
Why?
|
| Abortion, Induced | 4 | 2021 | 162 | 1.080 |
Why?
|
| Urban Health Services | 2 | 2019 | 47 | 0.940 |
Why?
|
| Family Planning Services | 2 | 2019 | 47 | 0.910 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2013 | 570 | 0.680 |
Why?
|
| Abortion, Spontaneous | 1 | 2021 | 74 | 0.660 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 296 | 0.630 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 126 | 0.580 |
Why?
|
| Physicians, Family | 3 | 2013 | 41 | 0.510 |
Why?
|
| Mass Screening | 1 | 2019 | 712 | 0.440 |
Why?
|
| Pregnancy | 7 | 2021 | 3241 | 0.400 |
Why?
|
| Pregnancy in Adolescence | 1 | 2013 | 27 | 0.390 |
Why?
|
| Contraceptive Agents, Female | 1 | 2013 | 31 | 0.390 |
Why?
|
| Physicians, Primary Care | 1 | 2013 | 110 | 0.350 |
Why?
|
| New York City | 4 | 2019 | 69 | 0.350 |
Why?
|
| Pregnancy, Unplanned | 1 | 2010 | 19 | 0.340 |
Why?
|
| Confidentiality | 1 | 2010 | 80 | 0.330 |
Why?
|
| Contraception, Barrier | 1 | 2010 | 1 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2013 | 649 | 0.320 |
Why?
|
| Family Practice | 1 | 2010 | 85 | 0.310 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 115 | 0.310 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 118 | 0.280 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 683 | 0.270 |
Why?
|
| Attitude to Health | 2 | 2008 | 227 | 0.270 |
Why?
|
| Health Care Surveys | 3 | 2013 | 296 | 0.240 |
Why?
|
| Adolescent | 7 | 2019 | 9888 | 0.230 |
Why?
|
| Young Adult | 5 | 2019 | 7001 | 0.200 |
Why?
|
| Female | 19 | 2021 | 49938 | 0.200 |
Why?
|
| Mifepristone | 1 | 2021 | 50 | 0.170 |
Why?
|
| Preconception Care | 1 | 2019 | 9 | 0.160 |
Why?
|
| Humans | 33 | 2021 | 95971 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.150 |
Why?
|
| Adult | 11 | 2019 | 28637 | 0.150 |
Why?
|
| Contraception | 1 | 2019 | 101 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 490 | 0.130 |
Why?
|
| Prostatic Neoplasms | 9 | 1995 | 1795 | 0.130 |
Why?
|
| Logistic Models | 1 | 2019 | 1263 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 1992 | 204 | 0.120 |
Why?
|
| United States | 2 | 2021 | 7762 | 0.100 |
Why?
|
| Drug Implants | 1 | 2013 | 38 | 0.100 |
Why?
|
| Aging | 2 | 2009 | 766 | 0.100 |
Why?
|
| Radiosurgery | 1 | 1996 | 311 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 65 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2013 | 375 | 0.090 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 226 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 107 | 0.090 |
Why?
|
| Gynecology | 1 | 2013 | 130 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2013 | 362 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 170 | 0.080 |
Why?
|
| Disclosure | 2 | 2010 | 111 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1991 | 158 | 0.080 |
Why?
|
| Vitamin D | 1 | 2012 | 273 | 0.080 |
Why?
|
| New York | 1 | 2010 | 76 | 0.080 |
Why?
|
| Telomere Shortening | 1 | 2009 | 25 | 0.080 |
Why?
|
| Focus Groups | 1 | 2010 | 191 | 0.080 |
Why?
|
| Fear | 1 | 2010 | 87 | 0.080 |
Why?
|
| Risk-Taking | 1 | 2010 | 163 | 0.080 |
Why?
|
| Mothers | 1 | 2010 | 155 | 0.080 |
Why?
|
| Mortality | 2 | 2009 | 153 | 0.070 |
Why?
|
| Telomere | 1 | 2009 | 121 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2010 | 165 | 0.070 |
Why?
|
| Patient Preference | 1 | 2010 | 126 | 0.070 |
Why?
|
| Leg | 1 | 2009 | 142 | 0.070 |
Why?
|
| Pediatrics | 1 | 2013 | 399 | 0.070 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2009 | 244 | 0.070 |
Why?
|
| Middle Aged | 10 | 2010 | 28255 | 0.070 |
Why?
|
| Male | 17 | 2013 | 45735 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2009 | 120 | 0.070 |
Why?
|
| Urban Population | 1 | 2009 | 240 | 0.070 |
Why?
|
| Supine Position | 2 | 1997 | 34 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 331 | 0.060 |
Why?
|
| Health | 1 | 2006 | 29 | 0.060 |
Why?
|
| Body Composition | 1 | 2006 | 75 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 636 | 0.060 |
Why?
|
| Social Justice | 1 | 2006 | 61 | 0.060 |
Why?
|
| Cognition | 1 | 2009 | 635 | 0.060 |
Why?
|
| Aged | 10 | 2012 | 20877 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 254 | 0.050 |
Why?
|
| Radiotherapy Dosage | 5 | 1995 | 482 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2012 | 4663 | 0.050 |
Why?
|
| Posture | 2 | 2009 | 130 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2008 | 2863 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2009 | 3901 | 0.040 |
Why?
|
| Equipment Design | 2 | 1997 | 427 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2012 | 7205 | 0.040 |
Why?
|
| Computer Terminals | 1 | 1997 | 7 | 0.030 |
Why?
|
| Immobilization | 1 | 1997 | 21 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 1992 | 566 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 1996 | 32 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 1997 | 130 | 0.030 |
Why?
|
| Technology, Radiologic | 1 | 1996 | 104 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 1993 | 1208 | 0.030 |
Why?
|
| Neutrons | 1 | 1995 | 57 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1995 | 82 | 0.030 |
Why?
|
| Photons | 1 | 1995 | 49 | 0.030 |
Why?
|
| Cause of Death | 2 | 2012 | 278 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 1993 | 2755 | 0.030 |
Why?
|
| Extremities | 1 | 1995 | 179 | 0.030 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 1993 | 25 | 0.030 |
Why?
|
| Sarcoma | 1 | 1995 | 220 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 292 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1995 | 284 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1993 | 49 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1993 | 91 | 0.020 |
Why?
|
| Tennessee | 1 | 2012 | 16 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2012 | 100 | 0.020 |
Why?
|
| Anemia | 1 | 1993 | 137 | 0.020 |
Why?
|
| Carcinoma | 1 | 1995 | 449 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 713 | 0.020 |
Why?
|
| Urethra | 1 | 1993 | 115 | 0.020 |
Why?
|
| Mediastinum | 1 | 1992 | 48 | 0.020 |
Why?
|
| Radiometry | 1 | 1992 | 61 | 0.020 |
Why?
|
| Chromatography, Paper | 1 | 1991 | 11 | 0.020 |
Why?
|
| Coitus | 1 | 1991 | 20 | 0.020 |
Why?
|
| Value of Life | 1 | 1991 | 23 | 0.020 |
Why?
|
| Social Values | 1 | 1991 | 44 | 0.020 |
Why?
|
| Genes, Retinoblastoma | 1 | 1991 | 21 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1991 | 89 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 3093 | 0.020 |
Why?
|
| Treatment Failure | 3 | 1995 | 296 | 0.020 |
Why?
|
| Vulva | 1 | 1990 | 23 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1990 | 19 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1991 | 272 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 1994 | 3142 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 844 | 0.020 |
Why?
|
| Combined Modality Therapy | 4 | 1995 | 1765 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 2 | 1997 | 1088 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1991 | 1050 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2009 | 20 | 0.020 |
Why?
|
| Postural Balance | 1 | 2009 | 52 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1991 | 930 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 549 | 0.020 |
Why?
|
| Base Sequence | 1 | 1991 | 2344 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 3041 | 0.020 |
Why?
|
| Brazil | 1 | 2006 | 82 | 0.010 |
Why?
|
| Educational Status | 1 | 2006 | 203 | 0.010 |
Why?
|
| Professional Competence | 1 | 2006 | 71 | 0.010 |
Why?
|
| Chicago | 1 | 2010 | 1504 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1991 | 2092 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2006 | 326 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2040 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 386 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 2641 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1990 | 1105 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 948 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 1995 | 1194 | 0.010 |
Why?
|
| Methods | 2 | 1993 | 149 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1995 | 1028 | 0.010 |
Why?
|
| Quality of Life | 1 | 1991 | 1817 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1995 | 1969 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 2464 | 0.010 |
Why?
|
| Neoplasms | 1 | 1995 | 3246 | 0.010 |
Why?
|
| Mutation | 1 | 1991 | 4371 | 0.010 |
Why?
|
| Computer Simulation | 2 | 1993 | 1158 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 66 | 0.010 |
Why?
|
| Radiobiology | 1 | 1995 | 13 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5949 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1995 | 192 | 0.010 |
Why?
|
| Vincristine | 1 | 1994 | 112 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1994 | 68 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 313 | 0.010 |
Why?
|
| Methotrexate | 1 | 1994 | 248 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 311 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 303 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1995 | 328 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 134 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1994 | 555 | 0.010 |
Why?
|
| Cisplatin | 1 | 1994 | 611 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 813 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 871 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 274 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 1101 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 2082 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 1995 | 10190 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1990 | 164 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1990 | 415 | 0.000 |
Why?
|
| Survival Rate | 1 | 1991 | 1978 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1991 | 2478 | 0.000 |
Why?
|